ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
US FDA denies approval for Tricida’s Veverimer
August 26, 2020Veverimer (TRC101), a non-absorbed, orally-administered polymer, is designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). -
Tricida Announces Publication of Positive Long-Term Phase 3 Clinical Trial Results of Veverimer (TRC101) in The Lancet
June 28, 2019Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed ... -
Tricida files for $150M IPO to fund kidney disease drug approval
June 11, 2018Tricida has filed to raise $150 million to bring a chronic kidney disease drug to market. Proceeds from the planned IPO will set Tricida up to file for FDA approval of TRC101 and start building up the 80- to 100-person sales team it wants to commercialize -
Tricida Announces $100 Million Venture Debt Financing From Hercules Capital
March 05, 2018Tricida, Inc. announced today that it has entered into a $100 million venture debt facility with Hercules Capital, Inc.
Pharma Sources Insight January 2025
